CD8A and neoplasm: Halofuginone treatment disrupted the tumor stromal barrier, decreased type I collagen, and broadened the intratumoral distribution of VSV-GFP. Combined treatment promoted DC maturation and CD8+ T cell activation, decreased Tregs, and increased animal survival.